Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term cardiac safety follow-up after SB3-G31-BC in HER2-positive early or locally advanced breast cancer
2015-005663-17Phase 3Completed
- Sponsor
- Samsung Bioepis
- Start
- Apr 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of trastuzumab and trastuzumab-dttb in breast cancer (2 cohorts), sponsored by Samsung Bioepis. Primary endpoint: Incidence of symptomatic congestive heart failure and asymptomatic LVEF decrease. Started Apr 2016; status: completed.
02
Drugs
trastuzumabtrastuzumab-dttb
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2015-005663-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005663-17.